Overview Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas Status: Recruiting Trial end date: 2024-11-20 Target enrollment: Participant gender: Summary This is an open-label, multicenter, phase 1b/2 trial of IMM01 (SIRPĪ± Fc) plus tislelizumab in patients with advanced solid tumors and lymphomas. Phase: Phase 1/Phase 2 Details Lead Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.